Skip to content
All resources

VIP

What Is VIP (Vasoactive Intestinal Peptide)? Structure, Receptors, Trials and Status

EW

By

· 6 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 6 sections
  1. What is VIP made of?
  2. How does VIP work?
  3. What has VIP been studied for?
  4. Is VIP approved anywhere?
  5. What is VIP commonly confused with?
  6. Frequently asked questions

VIP, vasoactive intestinal peptide, is a 28-amino-acid neuropeptide that Sami Said and Viktor Mutt isolated from pig small intestine in 1970, after noticing that an intestinal extract widened blood vessels (PMID 5450698). It turned out to be made far beyond the gut: by nerves in the lungs, the brain and around blood vessels, and by some immune cells. It belongs to the same family as secretin, glucagon and PACAP. Aviptadil is the international name for synthetic VIP. Its physiology is extensive; its clinical record is a set of trials in lung disease and critical illness, the largest of which did not meet their primary endpoints. It is not approved in Canada or the United States.

A 3D render of the branching airways inside the lungs
Illustration: the airways, one of the tissues where VIP-releasing nerves are dense.

What is VIP made of?

A single chain of 28 amino acids with the C-terminal end amidated, as in many signalling peptides. The sequence is identical in humans, pigs, cows and rats, which says something about how conserved its job is.

PropertyVIP
SequenceHSDAVFTDNYTRLRKQMAVKKYLNSILN, C-terminal amide
Also calledVasoactive intestinal peptide; vasoactive intestinal polypeptide; aviptadil (synthetic)
CAS number37221-79-7 (VIP); 40077-57-4 (aviptadil)
Molecular weightAbout 3,326 g/mol
FamilySecretin–glucagon family, with PACAP, secretin and glucagon
OriginIsolated from pig small intestine, 1970
Evidence stageExtensive physiology; human trials in lung disease and critical illness
Regulatory statusNot approved in Canada or the United States

In circulation it does not last long: it is cut quickly by peptidases, which is one reason most of its activity is local, near the nerve endings that release it.

How does VIP work?

Through two receptors, VPAC1 and VPAC2, which it shares with its close relative PACAP. Both are G-protein-coupled receptors that raise cyclic AMP inside the cell. They are found on intestinal epithelium, on smooth muscle in the airways and blood vessels, in the brain, and on T cells and macrophages. A third receptor, PAC1, binds PACAP strongly and VIP only weakly. Why one peptide acting on several receptors makes results hard to interpret is explained in how peptide receptors work.

What raising cyclic AMP does depends on the cell. In smooth muscle it relaxes the muscle, which is where the "vasoactive" in the name comes from. In intestinal epithelium it drives the secretion of water and salt. In immune cells, laboratory work has measured reduced release of inflammatory cytokines.

What has VIP been studied for?

AreaEvidence stageWhat exists
Gut secretion and motilityPhysiology, human diseaseVIP-secreting tumours (VIPomas) cause severe watery diarrhoea
Immune signallingCell and animalCytokine release from T cells and macrophages; rodent inflammation models
Pulmonary hypertensionSmall human studyA single-session study of 20 patients
COVID-19 respiratory failureRandomised trialsTwo US trials, one stopped for futility; one smaller trial in Turkey

The gut is where the physiology is clearest, and the best evidence is an accident of nature. Rare tumours that secrete VIP in large amounts, VIPomas, cause profuse watery diarrhoea and low potassium. That syndrome shows what the peptide does to intestinal secretion when there is far too much of it.

Pulmonary hypertension gave the first modern human data. Leuchte and colleagues studied 20 patients during right-heart catheterisation and reported a small, short-lived widening of the lung's blood vessels without a change in systemic blood pressure, and called for further studies (PMID 18978135). It was a single-session study, not a trial of an outcome.

COVID-19 produced the largest trials. Youssef and colleagues randomised 196 patients with critical respiratory failure in ten US hospitals to aviptadil or placebo; the primary endpoint, alive and free of respiratory failure at day 60, was not met, and the authors reported secondary and subgroup differences (PMID 36044317). The NIH-sponsored TESICO trial then randomised 461 patients at 28 US sites. Its data and safety monitoring board stopped the aviptadil comparison for futility: 38% of the aviptadil group and 36% of the placebo group had died by day 90 (PMID 37348524). A smaller trial of 80 hospitalised patients in Turkey reported a shorter time to discharge (PMID 39870064). When a large, independently run trial and smaller, sponsor-linked ones disagree, the larger one carries more weight; why is set out in how to read a peptide study.

Is VIP approved anywhere?

Not in Canada or the United States. In the US, the developer's request for emergency authorisation of aviptadil in COVID-19 was not granted. In some European countries aviptadil is authorised only as part of a combination product for an unrelated indication, which does not extend to VIP sold on its own. Status in Canada can be checked in the Drug Product Database, and the general framework is set out in peptides and Canadian law.

What is VIP commonly confused with?

PACAP. Pituitary adenylate cyclase-activating polypeptide shares about two-thirds of VIP's sequence and both of its main receptors. The two are separate peptides with separate genes.

Secretin and glucagon. Members of the same structural family, with their own receptors and very different jobs.

A "VIP" protocol. Online, the abbreviation is often attached to treatment programmes for specific illnesses. Those are claims about people, not about the peptide's literature, and none rests on a completed randomised trial.

Supplied here for laboratory use: VIP. For laboratory research use only.

The findings above describe the peptide in the cells, animals and people studied, not any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

What does VIP stand for? Vasoactive intestinal peptide. "Vasoactive" because it relaxes blood vessels; "intestinal" because it was first isolated from the intestine, although it is made throughout the body.

Is VIP the same as aviptadil? Aviptadil is the name for synthetic VIP with the human sequence. They are the same peptide.

Did aviptadil work in COVID-19? The largest trial, run by the US National Institutes of Health, was stopped for futility, with similar death rates in both groups. A 196-patient trial missed its primary endpoint. A smaller trial reported a shorter time to discharge.

Is VIP legal in Canada? It has no Canadian authorisation as a drug. It is sold here as a laboratory research chemical, not for human use.

Selected Research References

  1. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217-1218. pubmed.ncbi.nlm.nih.gov/5450698
  2. Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. European Respiratory Journal. 2008;32(5):1289-1294. pubmed.ncbi.nlm.nih.gov/18978135
  3. Youssef JG, Lavin P, Schoenfeld DA, et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Critical Care Medicine. 2022;50(11):1545-1554. pubmed.ncbi.nlm.nih.gov/36044317
  4. Brown SM, Barkauskas CE, Grund B, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respiratory Medicine. 2023;11(9):791-803. pubmed.ncbi.nlm.nih.gov/37348524
  5. Esendagli D, Sarı N, Akhan S, et al. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19. Medical Principles and Practice. 2025;34(2):191-200. pubmed.ncbi.nlm.nih.gov/39870064

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.